ACP3 and prostate carcinoma: Overexpression of C2GNT1 results in altered O-glycosylation of prostate-specific antigen (PSA), prostatic acidic phosphatase (PAP) and mucin 1 (MUC1) in prostate cancer cells (Chen et al., 2014).